Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has earned a consensus rating of “Buy” from the thirteen brokerages that are covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $51.90.
SUPN has been the topic of several recent research reports. BidaskClub downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, February 1st. FBR & Co initiated coverage on shares of Supernus Pharmaceuticals in a research report on Thursday, October 19th. They set a “buy” rating and a $53.00 price target on the stock. Zacks Investment Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $47.00 price target on the stock in a research report on Wednesday, November 8th. ValuEngine downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Finally, B. Riley boosted their price target on shares of Supernus Pharmaceuticals from $50.00 to $54.00 and gave the stock a “buy” rating in a research report on Thursday, December 28th.
Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) traded up $1.45 during trading hours on Tuesday, reaching $38.65. 433,100 shares of the company traded hands, compared to its average volume of 757,894. The company has a market cap of $1,960.00, a P/E ratio of 35.14 and a beta of 1.08. Supernus Pharmaceuticals has a 12-month low of $24.65 and a 12-month high of $50.04.
Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.27 by $0.02. The firm had revenue of $80.40 million for the quarter, compared to the consensus estimate of $78.74 million. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The firm’s quarterly revenue was up 41.5% on a year-over-year basis. sell-side analysts expect that Supernus Pharmaceuticals will post 1.07 EPS for the current fiscal year.
In other news, VP Padmanabh P. Bhatt sold 20,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Wednesday, January 17th. The shares were sold at an average price of $44.98, for a total value of $899,600.00. Following the transaction, the vice president now owns 32,500 shares of the company’s stock, valued at approximately $1,461,850. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Gregory S. Patrick sold 50,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, January 11th. The stock was sold at an average price of $43.56, for a total transaction of $2,178,000.00. The disclosure for this sale can be found here. Insiders sold a total of 165,750 shares of company stock worth $7,133,973 in the last ninety days. Corporate insiders own 6.70% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in SUPN. Vanguard Group Inc. grew its stake in shares of Supernus Pharmaceuticals by 39.1% in the 2nd quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock worth $150,873,000 after purchasing an additional 984,200 shares during the last quarter. Pictet Asset Management Ltd. increased its position in shares of Supernus Pharmaceuticals by 438.7% in the third quarter. Pictet Asset Management Ltd. now owns 491,283 shares of the specialty pharmaceutical company’s stock worth $19,651,000 after acquiring an additional 400,083 shares in the last quarter. Scout Investments Inc. increased its position in shares of Supernus Pharmaceuticals by 239.5% in the third quarter. Scout Investments Inc. now owns 565,900 shares of the specialty pharmaceutical company’s stock worth $22,636,000 after acquiring an additional 399,225 shares in the last quarter. Janus Henderson Group PLC purchased a new position in shares of Supernus Pharmaceuticals in the third quarter worth approximately $10,646,000. Finally, Royal Bank of Canada increased its position in shares of Supernus Pharmaceuticals by 790.8% in the second quarter. Royal Bank of Canada now owns 271,451 shares of the specialty pharmaceutical company’s stock worth $11,699,000 after acquiring an additional 240,978 shares in the last quarter. 98.20% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Supernus Pharmaceuticals Inc (SUPN) Receives Average Recommendation of “Buy” from Brokerages” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/20/supernus-pharmaceuticals-inc-supn-receives-average-recommendation-of-buy-from-brokerages.html.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.